Practical aspects of the use of amiodarone.

Abstract:

:Amiodarone is a class III antiarrhythmic drug with sympatholytic properties, which prolongs the refractory period of all cardiac tissues, depresses sinus node automaticity and atrioventricular nodal conduction. It is active on all cardiac arrhythmias, its use being limited by the risk of side effects, mainly extracardiac, which are dependent upon dosage and duration of treatment. The use of an oral loading dose of intravenous infusion to rapidly obtain an efficacious blood concentration may minimise the delay in onset of drug action. Amiodarone progressively accumulates in cardiac muscle and is eliminated slowly, allowing drug free periods (2 days a week) on long term therapy. Pharmacokinetic interaction with digoxin, class I antiarrhythmic drugs and warfarin must be considered during combination therapy, as well as the potentiation of electrophysiological effects when amiodarone is co-administered with combined calcium antagonists and beta-blockers.

journal_name

Drugs

journal_title

Drugs

authors

Puech P

doi

10.2165/00003495-199100412-00009

subject

Has Abstract

pub_date

1991-01-01 00:00:00

pages

67-73

eissn

0012-6667

issn

1179-1950

journal_volume

41 Suppl 2

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial.

    abstract:BACKGROUND:The combination of an inhaled corticosteroid (ICS) and a long-acting bronchodilator is recommended in the treatment of patients with chronic obstructive pulmonary disease (COPD) who have frequent exacerbations. Budesonide/formoterol dry powder inhaler (DPI) has demonstrated efficacy and tolerability in patie...

    journal_title:Drugs

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.2165/00003495-200868140-00004

    authors: Tashkin DP,Rennard SI,Martin P,Ramachandran S,Martin UJ,Silkoff PE,Goldman M

    更新日期:2008-01-01 00:00:00

  • Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double-blind placebo-controlled trial.

    abstract::Although venous thromboembolism has occasionally been reported after hospital discharge in patients who have undergone total hip replacement (THR), this risk has not been fully quantified and the usefulness of a prophylactic treatment has not been evaluated. We conducted a single-centre prospective randomised double-b...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-199600527-00009

    authors: Planes A,Vochelle N,Darmon JY,Fagola M,Bellaud M,Compan D,Saliba E,Weisslinger N,Huet Y

    更新日期:1996-01-01 00:00:00

  • Dulaglutide: A Review in Type 2 Diabetes.

    abstract::Subcutaneous dulaglutide (Trulicity®) is a once-weekly glucagon-like peptide-1 receptor agonist that is approved in numerous countries as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes (T2D). In the clinical trial and real-world settings, once-weekly subcutaneous dulaglutide, as monot...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01260-9

    authors: Scott LJ

    更新日期:2020-02-01 00:00:00

  • Rheumatoid arthritis: strategies in the management of patients showing an inadequate response to TNFalpha antagonists.

    abstract::The introduction of medications that target specific proinflammatory cytokines has revolutionized the management of patients with rheumatoid arthritis. The agents that antagonize the effects of tumour necrosis factor (TNF)-alpha -- infliximab, etanercept and adalimumab -- have consistently shown very good efficacy for...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200868050-00003

    authors: Lutt JR,Deodhar A

    更新日期:2008-01-01 00:00:00

  • Pharmacological and biochemical actions of sulphasalazine.

    abstract::This review considers recent pharmacological and biochemical studies of sulphasalazine and its colonic metabolites, 5-aminosalicylic acid and sulphapyridine, in relation to the use of the parent drug for the treatment of ulcerative colitis and, more recently, rheumatoid arthritis. Several factors make it difficult to ...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,评审

    doi:10.2165/00003495-198600321-00005

    authors: Hoult JR

    更新日期:1986-01-01 00:00:00

  • Postmenopausal hormone replacement therapy and cardiovascular risk reduction. A review.

    abstract::Administration of unopposed postmenopausal estrogen therapy protects against coronary heart disease (CHD) in women. This is mediated, in part, through beneficial effects on lipid and lipoprotein metabolism. Fewer data are available with regard to CHD risk reduction when a progesterone is required in addition to estrog...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199400472-00005

    authors: Kafonek SD

    更新日期:1994-01-01 00:00:00

  • Issues in patient compliance.

    abstract::Patient compliance refers to the willingness and ability of an individual to follow health-related advice, to take medication as prescribed, to attend scheduled clinic appointments and to complete recommended investigations. It is a major health issue, with outcomes related to levels of morbidity, mortality and cost u...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199754060-00002

    authors: Murphy J,Coster G

    更新日期:1997-12-01 00:00:00

  • Inotuzumab Ozogamicin: First Global Approval.

    abstract::Intravenous inotuzumab ozogamicin (Besponsa®; Pfizer) is an anti-CD22 monoclonal antibody-calicheamicin conjugate that binds to CD22-expressing tumour cells. Upon binding, the complex is internalised and the cytotoxic calicheamicin derivative is released inside the cell, inducing double-strand DNA breakage and subsequ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-017-0802-5

    authors: Lamb YN

    更新日期:2017-09-01 00:00:00

  • Drug treatment of stroke. Current status and future prospects.

    abstract::Despite advances in the understanding of the mechanism of cerebral injury during focal ischaemia, the best treatment of cerebral ischaemia is still prevention. The pathophysiological mechanisms that contribute to cerebral ischaemia are discussed relative to the many therapeutic interventions that have been attempted. ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198835040-00005

    authors: Sila CA,Furlan AJ

    更新日期:1988-04-01 00:00:00

  • Landiolol: A Review in Tachyarrhythmias.

    abstract::Intravenous landiolol [Rapibloc® (EU)], an ultra short-acting highly cardioselective β1-blocker, is approved in the EU for the rapid short-term control of tachyarrhythmias in the perioperative and intensive care settings. It has long been used in Japan to treat perioperative tachyarrhythmias. The efficacy of landiolol...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-018-0883-9

    authors: Syed YY

    更新日期:2018-03-01 00:00:00

  • Cenobamate: First Approval.

    abstract::Cenobamate (XCOPRI®) is an oral, small molecule neurotherapeutic azole compound that is being developed by SK Life Science Inc. and Arvelle Therapeutics for the treatment of epilepsy. Based on results of two pivotal phase 2 trials, cenobamate was recently approved in the USA for use in the treatment of partial-onset s...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01250-6

    authors: Keam SJ

    更新日期:2020-01-01 00:00:00

  • Current Status of Biosimilars in Oncology.

    abstract::Four medicinal cancer biological blockbusters will end their patent lifespan by 2020. It is estimated that the total market for cancer biologicals will reach approximately US$68 billion at that time. Approximately 20 biosimilars have entered the European market since the launch of the original approval guidelines in 2...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-017-0743-z

    authors: Camacho LH

    更新日期:2017-06-01 00:00:00

  • Panic disorder. Pathophysiology and drug treatment.

    abstract::Advances over the past 2 decades in our understanding of the biology of panic disorder have paralleled a remarkable increase in the development of new pharmacological agents with antipanic effects. Although we can not presently use biological tests to help with our choice of therapeutic agent for individual patients, ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199549030-00002

    authors: Johnson MR,Lydiard RB,Ballenger JC

    更新日期:1995-03-01 00:00:00

  • [Review of current pharmacologic treatment of pain].

    abstract::Pain is the main reason prompting patients to consult their physicians. In acute conditions, pain has a very particular significance as a warning sign, enabling the physician to attempt a diagnosis. Nevertheless, its detrimental effect upon the individual (even in the case of acute pain) and its cost to society are no...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199700532-00005

    authors: Brasseur L

    更新日期:1997-01-01 00:00:00

  • Chemotherapy in the management of bladder tumours.

    abstract::For patients with superficial bladder tumours intravesical treatment or prophylaxis with thiotepa, doxorubicin, mitomycin C or Bacillus Calmette-Guerin has added a useful dimension to management, although the precise indications for each regimen remain to be better defined. For patients with metastatic bladder cancer ...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,评审

    doi:10.2165/00003495-198938020-00009

    authors: Whitmore WF Jr,Yagoda A

    更新日期:1989-08-01 00:00:00

  • Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis.

    abstract::Glatiramer acetate is a synthetic analogue of the multiple sclerosis (MS)-associated antigen, myelin basic protein. It is indicated in the EU, US and many other countries to reduce the frequency of relapses in patients with relapsing-remitting MS (RRMS), and for the treatment of patients who have experienced a well de...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11204560-000000000-00000

    authors: Carter NJ,Keating GM

    更新日期:2010-08-20 00:00:00

  • Clopidogrel.

    abstract::Clopidogrel is a thienopyridine that irreversibly inhibits platelet aggregation by selectively binding to adenylate cyclase-coupled ADP receptors on the platelet surface. In animal models, clopidogrel reduced the formation of both arterial and venous thrombi. After oral administration, clopidogrel is rapidly absorbed ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199754050-00006

    authors: Coukell AJ,Markham A

    更新日期:1997-11-01 00:00:00

  • Meningococcal groups C and Y and haemophilus B tetanus toxoid conjugate vaccine (HibMenCY-TT; MenHibrix(®)): a review.

    abstract::The meningococcal groups C and Y and Haemophilus b (Hib) tetanus toxoid conjugate vaccine (HibMenCY-TT) contains Neisseria meningitidis serogroup C and Y capsular polysaccharide antigens, and Hib capsular polysaccharide [polyribosyl-ribitol-phosphate (PRP)]. The HibMenCY-TT vaccine is available in the USA for use as a...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-013-0048-9

    authors: Perry CM

    更新日期:2013-05-01 00:00:00

  • A randomised controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis.

    abstract::74 cirrhotic patients with a history of variceal or gastric bleeding were randomly assigned to treatment with propranolol (40 to 360 mg/day) or placebo. The patients were all in good condition and doses of propranolol were titrated until a 25% reduction in heart rate was achieved. After 2 years, the cumulative percent...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-198900372-00006

    authors: Lebrec D,Poynard T,Bernuau J,Bercoff E,Nouel O,Capron JP,Poupon R,Bouvry M,Rueff B,Benhamou JP

    更新日期:1989-01-01 00:00:00

  • New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities.

    abstract::Venous thromboembolism (VTE) is a major cause of morbidity, mortality, and healthcare expenditure. In the United States, approximately 0.1 % of the population experiences an initial VTE event each year. Anticoagulation therapy is the cornerstone of acute VTE treatment and for prevention of recurrent VTE events. Conven...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-014-0301-x

    authors: Dobesh PP,Fanikos J

    更新日期:2014-11-01 00:00:00

  • Drug-induced psychiatric disorders.

    abstract::This article is a review of the principal drug-induced psychiatric symptoms that are likely to be encountered in daily clinical practice as a result of drug abuse, overdoses or side effects of drugs prescribed for treatment. Many categories of medication have the potential to produce psychiatric symptoms, but antitube...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198122010-00004

    authors: Johnson DA

    更新日期:1981-07-01 00:00:00

  • Telavancin.

    abstract::Telavancin is the first available lipoglycopeptide antibacterial agent. It is active against Gram-positive bacteria, including meticillin/oxacillin-resistant Staphylococcus aureus (MRSA) strains associated with complicated skin and skin structure infections (cSSSIs). In randomized, double-blind trials, intravenous tel...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/10481380-000000000-00000

    authors: Lyseng-Williamson KA,Blick SK

    更新日期:2009-01-01 00:00:00

  • Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia.

    abstract:UNLABELLED:Zolpidem is an imidazopyridine agent that is indicated for the short term (< or = 4 weeks) treatment of insomnia (recommended dosage 10 mg/day in adults and 5 or 10 mg/day in the elderly or patients with hepatic impairment). Data have shown that the hypnotic efficacy of zolpidem is generally comparable to th...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200059040-00014

    authors: Holm KJ,Goa KL

    更新日期:2000-04-01 00:00:00

  • Simple analgesics.

    abstract::A number of drugs are available that act fairly specifically as "mild" analgesics, although this description by no means implies that their clinical effectiveness is limited to the relief of slight pain and trivial disability. They are effective by mouth and their action is mediated peripherally. Among the possible me...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197510050-00007

    authors: Parkhouse J

    更新日期:1975-01-01 00:00:00

  • Sickle cell disease in children.

    abstract::Early identification of infants with sickle cell disease (SCD) by newborn screening, now universal in all 50 states in the US, has improved survival, mainly by preventing overwhelming sepsis with the early use of prophylactic penicillin. Routine transcranial Doppler screening with the institution of chronic transfusio...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11632890-000000000-00000

    authors: Meier ER,Miller JL

    更新日期:2012-05-07 00:00:00

  • The role of arachidonic acid metabolites in gastrointestinal homeostasis. Biochemical, histological and clinical gastrointestinal effects.

    abstract::Metabolites of arachidonic acid have a broad range of physiological functions in the gastrointestinal tract, and seem to be involved in certain disturbances of gastrointestinal integrity and function. Prostaglandins inhibit gastric acid secretion, apparently via an adenylate cyclase-linked receptor, and also stimulate...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198700331-00007

    authors: Isselbacher KJ

    更新日期:1987-01-01 00:00:00

  • Upper respiratory tract infections. Ecological and therapeutic aspects of beta-lactamase production with special reference to Branhamella catarrhalis.

    abstract::Available data indicate that the most common beta-lactamase produced by Branhamella catarrhalis is plasmid mediated. The same enzyme occurs in Moraxella nonliquefaciens, a commensal in the upper respiratory tract. The ability to produce the enzyme, which is known as BRO-1, can be transferred by conjugation from M. non...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198600313-00026

    authors: Eliasson I,Kamme C

    更新日期:1986-01-01 00:00:00

  • Certolizumab pegol: a review of its use in the management of rheumatoid arthritis.

    abstract::Certolizumab pegol (Cimzia(®)) is a recombinant, polyethylene glycolylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor (TNF)-α. The drug is indicated for subcutaneous use every 2 or 4 weeks (q2w or q4w) for the treatment of adults with mo...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-013-0009-3

    authors: Deeks ED

    更新日期:2013-01-01 00:00:00

  • Monotherapy versus combination therapy as first line treatment of uncomplicated arterial hypertension.

    abstract::Mild to moderate hypertension still remains poorly controlled. This relates to multiple factors including low antihypertensive efficacy of single drug therapies reluctance of primary care physicians to modify/titrate initially chosen therapy to obtain target blood pressure, and poor compliance with medication. Several...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161070-00004

    authors: Ruzicka M,Leenen FH

    更新日期:2001-01-01 00:00:00

  • Oral antidiabetic agents: current role in type 2 diabetes mellitus.

    abstract::Type 2 diabetes mellitus is a progressive and complex disorder that is difficult to treat effectively in the long term. The majority of patients are overweight or obese at diagnosis and will be unable to achieve or sustain near normoglycaemia without oral antidiabetic agents; a sizeable proportion of patients will eve...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565030-00005

    authors: Krentz AJ,Bailey CJ

    更新日期:2005-01-01 00:00:00